Epilepsy is common in children, and about one-third of children do not have acceptable seizure control despite treatment with initial anti-seizure medications. This session will review multiple treatment options for children with treatment-resistant epilepsy. Such treatments can eliminate or substantially reduce seizures, reduce medication side-effects, optimize neurobehavioral function, and improve long-term outcomes. The treatments include newer anti-seizure medications, surgical procedures (resection, disconnection, and neuromodulation such as VNS, RNS, DBS), dietary treatment, and targeted management of specific genetic etiologies. Clinicians from CHOP’s Pediatric Epilepsy Program will provide summaries of each management approach including indications, our family-centered and inter-disciplinary approach to use, and outcomes.
- Summarize the treatments available to manage treatment-resistant epilepsy in children
- Review the appropriate role and expected outcomes of pediatric epilepsy surgery
- Describe how each advanced treatment can be selected and tailored to specific patients
- Sudha K. Kessler, MD, MSCE
- Benjamin C. Kennedy, MD
- Marissa P. DiGiovine, MD
- Christina Bergqvist, MD
- Ingo Helbig, MD
This seminar focuses on neurology and was delivered at a virtual event titled, “Managing Treatment Resistant Epilepsy,” on May 26, 2021.
Additional CHOP Resources:
- Epilepsy Neurogenetics Initiative (ENGIN)
- Pediatric Epilepsy Program
- Upcoming Healthcare Professionals Events
By starting this module, you agree to our Content Disclaimer and Terms of Service.
If this is your first time attempting to login to the new website with an existing account, you will first need to reset your password before logging in.Lost Your Password?
**By selecting “Yes”, you consent to receive information from CHOP. Once you have decided to receive such communications, you may later decide to stop receiving these communications. If you want to stop receiving these communications, you may send an email message to email@example.com.